(Q37681583)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Annie Im

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

481-488

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

A single amino acid that determines the sensitivity of progesterone receptors to RU486.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Sequence and characterization of a coactivator for the steroid hormone receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Formation of the androgen receptor transcription complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Early pregnancy termination with mifepristone and misoprostol in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Medical management of early pregnancy failure: efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Levonorgestrel and mifepristone in emergency contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Systematic review of mifepristone for the treatment of uterine leiomyomata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Medical termination of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Rates of serious infection after changes in regimens for medical abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

Medical abortion and the risk of subsequent adverse pregnancy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903535880

10.1517/14656560903535880

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102310%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference